Healios K.K.
4593.TJPXHealthcareBiotechnology
Latest quote
¥267
−¥3.00 · -1.11%
4593.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteHealios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Tadahisa S. Kagimoto
- Listed since
- Jun 16, 2015
- Employees
- 75
Market position
Day range
Current ¥267
52-week range
Current ¥267
- Open
- ¥271
- Previous close
- ¥270
- Volume
- 1.45M
- 0.85× average
- Average volume
- 1.7M
- Average daily volume
- Market cap
- 36.05B JPY
- Beta
- 1.42
- Market reference 1
- 50-day average
- ¥253.7
- +5.24% above average
- 200-day average
- ¥337.62
- -20.92% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 26.43B JPY
- P/E (TTM)
- 53.83×
- P/B (TTM)
- 4.11×
- P/S (TTM)
- 610.94×
- EV / EBITDA
- -8.45×
- Earnings yield
- -7.52%
- Free cash flow yield
- -11.30%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -577.97%
- Operating margin
- -7110.17%
- Net margin
- 349.15%
- Return on equity
- -45.34%
- Return on assets
- -13.00%
- Return on invested capital
- -23.60%
Financial health
- Debt / equity
- 0.29×
- Current ratio
- 2×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 104M JPY | 560M JPY | 121M JPY | 90M JPY | 41M JPY |
| Cost of goods sold | 493M JPY | 128M JPY | 13M JPY | — | — |
| Gross profit | −389M JPY | 432M JPY | 108M JPY | 90M JPY | 41M JPY |
| Research and development | 2.02B JPY | 1.96B JPY | 2.3B JPY | 3.81B JPY | 3.7B JPY |
| Selling, general, and administrative | 1.27B JPY | 1.37B JPY | 1.18B JPY | 1.45B JPY | 1.72B JPY |
| Operating expenses | 3.01B JPY | 3.33B JPY | 3.49B JPY | 5.27B JPY | 5.43B JPY |
| Interest income | 1.42B JPY | 373M JPY | 456M JPY | 346M JPY | 1.73B JPY |
| Interest expense | 200M JPY | 1.59B JPY | 704M JPY | 500M JPY | 802M JPY |
| Depreciation and amortization | 275M JPY | 297M JPY | 224M JPY | 386M JPY | 262M JPY |
| Operating income | −3.4B JPY | −2.9B JPY | −3.38B JPY | −5.18B JPY | −5.38B JPY |
| Net income | −2.22B JPY | −4.24B JPY | −3.82B JPY | −5.17B JPY | −4.91B JPY |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 45%
- 5 beats, 6 misses, 0 met estimates
- Average EPS surprise
- +1.46%
- 11 comparable reports
- Latest EPS result
- 9.92
- Estimate -2.38 · Beat by 516.92%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
4593.T peers
ETFs holding 4593.T
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research 4593.Tresearch.disclaimer